Topic-Based
Resource Centers

Oral Anticoagulation in Atrial Fibrillation

Resource Center Toolbox TOOLBOX

 

 


Download PDF

 

Patients with atrial fibrillation are at increased risk of stroke and thomboembolic events. Two risk stratification tools for stroke and one for bleeding can assist clinicians to prescribe therapeutic regimens that balance stroke prevention against bleeding risk.

 

RELATED TOPICS

 

F1000Prime

Continually updated recommendations of the best research in biology and medicine from a faculty of global experts.

The following article has been evaluated by Paulus Kirchhof, MD, University Hospital Muenster, Germany, as well as other esteemed peer-selected Faculty Members who share their expert opinions and interpretations of the latest research. To read more, click here for all evaluations.

 
Apixaban versus warfarin in patients with atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

 

Warfarin and other vitamin K antagonists are highly effective treatments, but their use is limited by a narrow therapeutic range, drug and food interactions, required monitoring, and risk of bleeding. In the ARISTOTLE trial, the authors compared apixaban with warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one additional risk factor for stroke. More...

 

CLINICAL ARTICLES
Updated Strategies for Managing Nonvalvular Atrial Fibrillation in Primary Care

Updated Strategies for Managing Nonvalvular Atrial Fibrillation in Primary Care

 

A survey among healthcare providers and patients indicates there is a need for better communication with patients about AF and stroke since less than half of the patients in the survey report asking about their own risk of stroke or ask about stroke prevention. Risk stratification systems for stroke and bleeding help physicians to engage a more informed decision-making process with their patients. More...
 
 
Novel and Emerging Oral Anticoagulation Therapy in Atrial Fibrillation: Clinical Perspectives for Primary Care

Novel and Emerging Oral Anticoagulation Therapy in Atrial Fibrillation: Clinical Perspectives for Primary Care

 

Two new classes of oral anticoagulants—direct factor IIa (thrombin) inhibitors and factor Xa inhibitors—promise safe, easy to use, and effective alternatives to warfarin for treating nonvalvular AF. These agents, with their predictable drug profiles that allow for fixed dosing and no therapeutic monitoring, offer new approaches to AF in primary care. More...
 
 

 

CME

 

Case Study: Managing Stroke Risk in a Patient with Atrial Fibrillation and a Contraindication to Warfarin Anticoagulation

 

Release Date: January 31, 2012
Expiration Date: January 30, 2013

 

Contraindications to anticoagulation are common among elderly patients with atrial fibrillation. The "ideal" candidate for anticoagulation is the exception rather than the rule. In this case-based TxReporter, Robert G. Hart, MD, presents a complex case and models how to make challenging risk-versus-benefit treatment decisions. This Tx Reporter is the second of three e-newsletters in The Advanced Curriculum Program: Stroke Prevention in Atrial Fibrillation.

 


VIEW THIS ACTIVITY

CONTRIBUTOR

CONTRIBUTOR

EDITORIAL SUPPORT

Alexander Turpie, MD, FRCPC

Dr. Turpie is a professor of medicine at McMaster University, and an internist on the staff of Hamilton Health Sciences, Hamilton, Ontario. More...

David C. Willis, MD

Dr. Willis practices family medicine in Ocala, Fla. He serves as medical director for Healthy Ocala, a developing patient-centric health information exchange in north central Florida. More...

Deborah Kaplan

Editorial and media consultant